We have discovered and advanced multiple targeted therapies into clinical trials including Abivertinib for lung cancer and AC0058 for lupus disease.
We are passionate about bringing patients with cancer and autoimmune diseases treatments that can improve their overall health and quality of life.
We support healthcare providers through Investor Initiated Trials (IIT) to enhance the medical and scientific knowledge of our late-stage clinical programs.
ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases.
Learn about our Product Candidates
Novel EGFR tyrosine kinase inhibitor AC0010 displays high efficacy, tolerability, and safety in phase I/II clinical trials. ACEA Biosciences, Inc. presented today updated efficacy and safety data from its phase I/II dose escalation and expansion clinical trial… Read more
Clinical trial results for novel EGFR inhibitor AC0010 will be presented December 7th at World Conference on Lung Cancer. ACEA Biosciences, Inc. announced today that it will be presenting updated efficacy and safety data from its Phase I/II clinical trials… Read more